Douglas B Johnson Selected Research

Douglas B Johnson Research Topics

Disease

127	Melanoma (Melanoma, Malignant) 10/2022 - 06/2013
117	Neoplasms (Cancer) 10/2022 - 06/2013
15	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2015
10	Myocarditis (Carditis) 10/2022 - 11/2016
10	Disease Progression 11/2021 - 12/2013
6	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2017
6	COVID-19 01/2022 - 01/2020
6	Pneumonia (Pneumonitis) 01/2021 - 11/2019
5	Infections 03/2021 - 11/2018
5	Inflammation (Inflammations) 01/2020 - 09/2015
4	Autoimmune Diseases (Autoimmune Disease) 09/2022 - 02/2016
4	Lung Neoplasms (Lung Cancer) 01/2022 - 05/2020
4	Colitis 01/2021 - 01/2017
3	Heart Failure 01/2022 - 11/2017
3	Neutropenia 03/2021 - 01/2021
3	Renal Cell Carcinoma (Grawitz Tumor) 02/2021 - 01/2017
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 08/2020 - 06/2015
3	Encephalitis (Encephalitis, Rasmussen) 04/2020 - 01/2019
3	Drug-Related Side Effects and Adverse Reactions 01/2020 - 01/2019
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 12/2014
3	Breast Neoplasms (Breast Cancer) 01/2019 - 09/2017
3	Uveal melanoma 01/2018 - 11/2016
2	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 10/2019
2	Nausea 01/2022 - 11/2017
2	Obesity 01/2022 - 01/2018
2	Diarrhea 01/2022 - 01/2017
2	Hypertension (High Blood Pressure) 01/2022 - 10/2019
2	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2021 - 02/2016
2	Immune System Diseases (Immune Disorders) 01/2021 - 11/2019
2	Hepatitis 01/2021 - 12/2019
2	Interstitial Nephritis (Tubulointerstitial Nephritis) 10/2020 - 01/2020
2	Myositis (Idiopathic Inflammatory Myopathies) 08/2020 - 01/2018
2	Skin Neoplasms (Skin Cancer) 08/2020 - 04/2018
2	Virus Diseases (Viral Diseases) 05/2020 - 01/2017
2	Myasthenia Gravis 04/2020 - 11/2015
2	Hypophysitis 01/2019 - 05/2015
2	Fibrosis (Cirrhosis) 11/2017 - 01/2016
2	Carcinoma (Carcinomatosis) 11/2017 - 05/2017
1	Cardiotoxicity 10/2022
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2022
1	Anemia 01/2022
1	Fatigue 01/2022
1	Exanthema (Rash) 01/2022
1	Edema (Dropsy) 01/2022

Drug/Important Bio-Agent (IBA)

86	Immune Checkpoint InhibitorsIBA 10/2022 - 12/2013
29	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 06/2013
29	IpilimumabIBA 01/2022 - 12/2013
18	NivolumabIBA 01/2022 - 03/2015
16	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2014
16	LigandsIBA 01/2021 - 09/2015
14	AntibodiesIBA 01/2022 - 01/2016
10	pembrolizumabIBA 01/2022 - 01/2016
10	SteroidsIBA 01/2021 - 11/2017
10	trametinibIBA 01/2021 - 06/2013
9	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 11/2014
9	dabrafenibIBA 01/2021 - 06/2013
8	VemurafenibIBA 01/2021 - 06/2013
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2017
7	Programmed Cell Death 1 ReceptorIBA 12/2021 - 01/2018
7	Mitogen-Activated Protein KinasesIBA 01/2019 - 06/2013
6	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2022 - 05/2015
6	B7-H1 AntigenIBA 01/2020 - 03/2015
5	Biological ProductsIBA 12/2021 - 01/2016
4	AntigensIBA 01/2021 - 01/2017
4	Phosphotransferases (Kinase)IBA 01/2019 - 09/2015
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 06/2015
4	Pharmaceutical PreparationsIBA 01/2019 - 01/2014
3	Monoclonal AntibodiesIBA 01/2022 - 01/2017
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2019
3	CTLA-4 AntigenIBA 12/2021 - 01/2017
3	Interleukin-2 (IL2)IBA 02/2021 - 05/2014
3	InterferonsIBA 01/2021 - 01/2019
3	atezolizumabIBA 01/2021 - 01/2018
3	talimogene laherparepvecIBA 09/2019 - 01/2015
3	Codon (Codons)IBA 01/2019 - 04/2015
2	CateninsIBA 01/2022 - 04/2016
2	binimetinibIBA 01/2022 - 01/2021
2	GlucocorticoidsIBA 11/2021 - 11/2017
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 03/2021 - 01/2021
2	Abatacept (Orencia)FDA Link 01/2021 - 01/2019
2	Cancer VaccinesIBA 10/2020 - 01/2016
2	Blocking AntibodiesIBA 01/2020 - 11/2016
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019 - 11/2016
2	ParaffinIBA 01/2019 - 10/2017
2	Formaldehyde (Formol)FDA Link 01/2019 - 10/2017
2	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2017
2	HLA-DR Antigens (HLA-DR)IBA 11/2018 - 01/2016
2	MicroRNAs (MicroRNA)IBA 02/2015 - 11/2014
1	omega-Chloroacetophenone (Mace)IBA 10/2022
1	2- (5- (3- chlorophenyl)- 6- (4- chlorophenyl)- 1- (1- (isopropylsulfonyl)- 3- methylbutan- 2- yl)- 3- methyl- 2- oxopiperidin- 3- yl)acetic acidIBA 10/2022
1	beta CateninIBA 01/2022
1	ribociclibIBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022

Therapy/Procedure

123	Therapeutics 10/2022 - 06/2013
46	Immunotherapy 01/2022 - 09/2015
9	Drug Therapy (Chemotherapy) 01/2022 - 06/2013
4	Radiotherapy 01/2021 - 05/2015
2	Aftercare (After-Treatment) 01/2020 - 11/2016
2	Intralesional Injections 09/2019 - 01/2015
1	Craniotomy 01/2022